Tuesday, November 15, Lunch Symposium
What implications do the five-year patency rates of heparin-bonded ePTFE femoropopliteal bypass grafts have on axillobifemoral procedures? Russell Samson, MD, RVT, Sarasota, Florida
A multicenter predictive score for CLI patients: Should heparin-bonded ePTFE grafts be the first choice conduit for surgical bypass? Professor Walter Dorigo, Florence, Italy Professor Carlo Pratesi, Florence, Italy
Evening Event, 6:15 pm
Pioneering Innovation: A celebration of excellence and advancements
After a day of sitting, give yourself a boost – stretch your legs, and join us to celebrate the passion that drives innovation. Hear the stories from leading innovators as we honor the winners of Pioneers in Performance – North America. Experience firsthand how advancements are making a difference in the lives of others and discover our newest available products. This not-to-be-missed, vibrant, and inspirational evening promises to be the highlight event of the year, reigniting passion for innovation, together.
Learn more about the distinguished physicians being honored for their unrelenting dedication to advancing vascular and endovascular therapy at pioneersinperformance.com.
Wednesday, November 16, Lunch Symposium
Complex peripheral artery disease intervention: Improving outcomes through innovation Moderator: Frank J. Veith, MD, New York, New York Moderator: Michael B. Silva, Jr., MD, Galveston, Texas
Complex SFA intervention with an open-cell stent: Targeted landing and durable outcomes with a dual component, next generation vascular stent Arun Chervu, MD, Atlanta, Georgia
Complex SFA intervention with a stent-graft: How Japanese physicians achieved 88% primary patency in long lesions through optimal technique Hiroyoshi Yokoi, MD, Fukuoka, Japan
Evening Event, 6:15 pm
Together. Improving Life: Uniting our story with yours – a collaboration event.
Can one patient make a difference for the many? How can we improve lives and help create a better future for healthcare? What does it mean to be genuinely curious and deeply imaginative? These are the questions that have inspired us for more than 40 years, and will for years to come.
Hear from a triathlete, who after being diagnosed with four aneurysms repaired with our AAA device and first FDA-approved iliac branch endoprosthesis, continued with his training and competed in multiple triathlons after his repair. We invite you to join us for this event that showcases the real-life experience of a patient, his physician, and associates who bring to life our promise: Together. Improving Life
Thursday, November 17, Lunch Symposium
Examining the evidence: Should hypogastric preservation be the standard of care? Darren Schneider, MD, New York, New York
Exploring the feasibility of the GORE® TAG® Thoracic Branch Endoprosthesis and GORE® EXCLUDER® Thoracoabdominal Branch Endoprosthesis * Gustavo Oderich, MD, Rochester, Minnesota
* Caution: Investigational Device. Limited by United States law to Investigational Use.
Pavilion is in-use for invitation only event.
Friday, November 18, Lunch Symposium
Insights from Latin America Chairman: Bonno Van Bellen, MD, São Paulo, SP, Brazil Moderator: Prof. Juan Parodi, MD, Buenos Aires, Argentina
What are the common predictors of leg outcome after elective EVAR? Felipe Zoppas, MD, Caixas do Sul, RS, Brazil
How effective is the GORE® VIABAHN® Endoprosthesis with Heparin Bioactive Surface for endovascular treatment of popliteal aneurysms? Antonio Freitas, MD, Rio de Janeiro, RJ, Brazil
This just in: Aortic disease awareness campaign is having an impact in Mexico Carlos Hinojosa, MD, Mexico City, Mexico
New insights: My first experience with the GORE® EXCLUDER® Iliac Branch Endoprosthesis (IBE) in Puerto Rico Angel Menendez, MD, San Juan, Puerto Rico
Saturday, November 19, Lunch Symposium
Exploring innovative technologies for complex dialysis access cases Achieving durable outcomes in complex AV access interventions with the GORE® VIABAHN® Endoprosthesis John Aruny, MD, New Haven, Connecticut
Why the GORE® Hybrid Vascular Graft is an effective choice for treating disadvantaged venous anatomy David Leeser, MD, Baltimore, Maryland